… for the treatment of cancer. In this review, we will focus on recent advances in the field of
NK cell immunotherapy, including augmentation of antibody-dependent cellular cytotoxicity, …

… complex (MHC) on the surface of antigen-presenting cells or tumor cells. The first TCR T
cell cancer immunotherapy used in the clinic was tested against metastatic melanoma and …

The use of dendritic cells (DCs) for tumor immunotherapy represents a powerful approach
for harnessing the patient‘s own immune system to eliminate tumor cells. However, …

… and destroy tumor cells has been the central goal of anti-cancer immunotherapy. In recent
… feasible treatment. One of the main treatment modalities within cancer immunotherapy has …

… and discuss future directions in adoptive cell transfer based cancer immunotherapy. … T
cells. In this review, we will highlight recent advances in ACT-based cancer immunotherapy and …

… combinations of targeted therapies and immunotherapies for the treatment of cancer. … By
contrast, cancer immunotherapies can elicit durable responses in subsets of treated patients …

… This review will focus on cellular immunotherapies involving the use of T cells and
natural killer (NK) cells in adoptive cell transfer, as well as briefly focussing on DC vaccines. …

… treatment failure, as most drugs target cells of active proliferation. Immunotherapy has shown
great potential in cancer … effector cells is less affected by the metabolic status of cancer cells…

… as cancer chemotherapy began with the use of single agents and evolved into combination
therapy, so immunotherapeutic … of CY and cancer vaccines such as autologous tumor cells, …

… In an effort to revert the functional anergy of NK cells within MHC-deficient tumors, we treated
tumor-bearing mice with pro-inflammatory cytokines. Some mice received a combination of …